RU2018107711A - PIPERAZINE DERIVATIVE - Google Patents
PIPERAZINE DERIVATIVE Download PDFInfo
- Publication number
- RU2018107711A RU2018107711A RU2018107711A RU2018107711A RU2018107711A RU 2018107711 A RU2018107711 A RU 2018107711A RU 2018107711 A RU2018107711 A RU 2018107711A RU 2018107711 A RU2018107711 A RU 2018107711A RU 2018107711 A RU2018107711 A RU 2018107711A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- substituted
- compound
- halogen
- pyrrolidin
- Prior art date
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 44
- 150000001875 compounds Chemical class 0.000 claims 27
- 229910052799 carbon Inorganic materials 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 17
- 150000002367 halogens Chemical class 0.000 claims 17
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 5
- -1 1,6-dihydro-6-oxopyridazinyl Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 210000001635 urinary tract Anatomy 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- ADUOPKMZFRVUSL-NNNZQYNTSA-N (2S)-2-[(3S)-4-[(3S,4R)-1-tert-butyl-4-(4-chloro-2-fluorophenyl)pyrrolidine-3-carbonyl]-3-methylpiperazin-1-yl]-3-(2,4,6-trimethylphenyl)propanoic acid Chemical compound C(C)(C)(C)N1C[C@H]([C@@H](C1)C1=C(C=C(C=C1)Cl)F)C(=O)N1[C@H](CN(CC1)[C@H](C(=O)O)CC1=C(C=C(C=C1C)C)C)C ADUOPKMZFRVUSL-NNNZQYNTSA-N 0.000 claims 2
- NSIPBHNJNZCBMA-UAUZMGQXSA-N (2S)-2-[(3S)-4-[(3S,4R)-1-tert-butyl-4-(4-chloro-2-fluorophenyl)pyrrolidine-3-carbonyl]-3-methylpiperazin-1-yl]-3-(2-fluoro-4-methylphenyl)propanoic acid Chemical compound C(C)(C)(C)N1C[C@H]([C@@H](C1)C1=C(C=C(C=C1)Cl)F)C(=O)N1[C@H](CN(CC1)[C@H](C(=O)O)CC1=C(C=C(C=C1)C)F)C NSIPBHNJNZCBMA-UAUZMGQXSA-N 0.000 claims 2
- FKQOUTBMWUASHL-NIXYAPBQSA-N (2S)-2-[(3S)-4-[(3S,4R)-1-tert-butyl-4-(4-chloro-2-fluorophenyl)pyrrolidine-3-carbonyl]-3-methylpiperazin-1-yl]-3-(4-methylphenyl)propanoic acid Chemical compound C(C)(C)(C)N1C[C@H]([C@@H](C1)C1=C(C=C(C=C1)Cl)F)C(=O)N1[C@H](CN(CC1)[C@H](C(=O)O)CC1=CC=C(C=C1)C)C FKQOUTBMWUASHL-NIXYAPBQSA-N 0.000 claims 2
- SDHWYNKMRJOEAU-NWAHNDBCSA-N (2S)-2-[(3S)-4-[(3S,4R)-4-(4-chloro-2-fluorophenyl)-1-(oxan-4-yl)pyrrolidine-3-carbonyl]-3-methylpiperazin-1-yl]-3-(2-fluoro-4,6-dimethylphenyl)propanoic acid Chemical compound ClC1=CC(=C(C=C1)[C@H]1[C@@H](CN(C1)C1CCOCC1)C(=O)N1[C@H](CN(CC1)[C@H](C(=O)O)CC1=C(C=C(C=C1C)C)F)C)F SDHWYNKMRJOEAU-NWAHNDBCSA-N 0.000 claims 2
- PZRIXOAEIPPDAC-PJBRVGGZSA-N (2S)-2-[(3S)-4-[(3S,4R)-4-(4-chloro-2-fluorophenyl)-1-(oxan-4-yl)pyrrolidine-3-carbonyl]-3-methylpiperazin-1-yl]-3-(2-fluoro-4-methylphenyl)propanoic acid Chemical compound ClC1=CC(=C(C=C1)[C@H]1[C@@H](CN(C1)C1CCOCC1)C(=O)N1[C@H](CN(CC1)[C@H](C(=O)O)CC1=C(C=C(C=C1)C)F)C)F PZRIXOAEIPPDAC-PJBRVGGZSA-N 0.000 claims 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- FTQFOEKMFLMGME-JXWHJRSQSA-N (2S)-2-[(3S)-4-[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-carbonyl]-3-methylpiperazin-1-yl]-3-(2,3-dihydro-1H-inden-5-yl)propanoic acid Chemical compound C(C)(C)(C)N1C[C@H]([C@@H](C1)C1=C(C=C(C=C1)F)F)C(=O)N1[C@H](CN(CC1)[C@H](C(=O)O)CC=1C=C2CCCC2=CC=1)C FTQFOEKMFLMGME-JXWHJRSQSA-N 0.000 claims 1
- FPSKGXUIOROROW-UMGNPTPLSA-N (2S)-2-[(3S)-4-[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-carbonyl]-3-propylpiperazin-1-yl]-3-naphthalen-2-ylpropanoic acid Chemical compound C(C)(C)(C)N1C[C@H]([C@@H](C1)C1=C(C=C(C=C1)F)F)C(=O)N1[C@H](CN(CC1)[C@H](C(=O)O)CC1=CC2=CC=CC=C2C=C1)CCC FPSKGXUIOROROW-UMGNPTPLSA-N 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (105)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-154601 | 2015-08-04 | ||
JP2015154601 | 2015-08-04 | ||
PCT/JP2016/072569 WO2017022733A1 (en) | 2015-08-04 | 2016-08-02 | Piperazine derivative |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2018107711A true RU2018107711A (en) | 2019-09-05 |
RU2018107711A3 RU2018107711A3 (en) | 2019-11-21 |
RU2731913C2 RU2731913C2 (en) | 2020-09-09 |
Family
ID=57943013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018107711A RU2731913C2 (en) | 2015-08-04 | 2016-08-02 | Piperazine derivative |
Country Status (20)
Country | Link |
---|---|
US (1) | US10301286B2 (en) |
EP (1) | EP3333165B1 (en) |
JP (1) | JP6693520B2 (en) |
KR (1) | KR20180032585A (en) |
CN (1) | CN107849018B (en) |
AR (1) | AR105582A1 (en) |
AU (1) | AU2016302648A1 (en) |
CA (1) | CA2995188A1 (en) |
CO (1) | CO2018002416A2 (en) |
ES (1) | ES2753227T3 (en) |
HK (1) | HK1251548A1 (en) |
IL (1) | IL257264A (en) |
MX (1) | MX2018001503A (en) |
PH (1) | PH12018500239A1 (en) |
PL (1) | PL3333165T3 (en) |
PT (1) | PT3333165T (en) |
RU (1) | RU2731913C2 (en) |
SG (1) | SG11201800882YA (en) |
TW (1) | TW201718548A (en) |
WO (1) | WO2017022733A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109563074B (en) | 2016-07-19 | 2021-09-28 | 安斯泰来制药株式会社 | Piperazine derivatives |
CN112824530A (en) * | 2019-11-20 | 2021-05-21 | 中国科学院深圳先进技术研究院 | HEK293F suspension cell high-efficiency electrotransfection method |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6911447B2 (en) * | 2001-04-25 | 2005-06-28 | The Procter & Gamble Company | Melanocortin receptor ligands |
US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
DE60308996T2 (en) * | 2002-01-23 | 2007-05-10 | Eli Lilly And Co., Indianapolis | melanocortin |
US7132539B2 (en) * | 2002-10-23 | 2006-11-07 | The Procter & Gamble Company | Melanocortin receptor ligands |
WO2004078717A1 (en) | 2003-03-03 | 2004-09-16 | Merck & Co., Inc. | Acylated piperazine derivatives as melanocortin-4 receptor agonists |
CN1816337A (en) * | 2003-05-01 | 2006-08-09 | 帕拉坦技术公司 | Naphthalene-containing melanocortin receptor-specific small molecule |
WO2005102340A1 (en) * | 2003-05-30 | 2005-11-03 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
WO2005040109A1 (en) * | 2003-10-22 | 2005-05-06 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
GB0402492D0 (en) | 2004-02-04 | 2004-03-10 | Pfizer Ltd | Pharmaceutically active compounds |
CA2574156A1 (en) * | 2004-07-19 | 2006-02-23 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
US20080234280A1 (en) * | 2005-08-01 | 2008-09-25 | Mcmurray Gordon | Use of Mc4 Receptor Agonist Compounds |
JP2009510069A (en) * | 2005-09-30 | 2009-03-12 | メルク エンド カムパニー インコーポレーテッド | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
JP5243274B2 (en) * | 2006-02-23 | 2013-07-24 | ファイザー・リミテッド | Piperidinoylpyrrolidine, a type 4 melanocortin receptor agonist |
CA2642922C (en) | 2006-02-23 | 2011-08-02 | Pfizer Limited | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines |
AU2007300529A1 (en) | 2006-09-27 | 2008-04-03 | Merck Sharp & Dohme Corp. | Acylated piperidine derivatives as melanocortin-4 receptor modulators |
MX2011001405A (en) | 2008-08-06 | 2011-03-21 | Pfizer Ltd | Diazepine and diazocane compounds as mc4 agonists. |
MY193597A (en) | 2014-05-29 | 2022-10-19 | Mitsubishi Tanabe Pharma Corp | Novel pyrrolidine compound and application as melanocortin receptor agonist |
-
2016
- 2016-08-02 EP EP16833012.4A patent/EP3333165B1/en active Active
- 2016-08-02 PL PL16833012T patent/PL3333165T3/en unknown
- 2016-08-02 SG SG11201800882YA patent/SG11201800882YA/en unknown
- 2016-08-02 US US15/749,375 patent/US10301286B2/en active Active
- 2016-08-02 KR KR1020187003183A patent/KR20180032585A/en not_active Application Discontinuation
- 2016-08-02 WO PCT/JP2016/072569 patent/WO2017022733A1/en active Application Filing
- 2016-08-02 ES ES16833012T patent/ES2753227T3/en active Active
- 2016-08-02 CN CN201680045994.6A patent/CN107849018B/en active Active
- 2016-08-02 PT PT168330124T patent/PT3333165T/en unknown
- 2016-08-02 JP JP2017533072A patent/JP6693520B2/en not_active Expired - Fee Related
- 2016-08-02 AU AU2016302648A patent/AU2016302648A1/en not_active Abandoned
- 2016-08-02 MX MX2018001503A patent/MX2018001503A/en active IP Right Grant
- 2016-08-02 CA CA2995188A patent/CA2995188A1/en not_active Abandoned
- 2016-08-02 RU RU2018107711A patent/RU2731913C2/en active
- 2016-08-03 AR ARP160102367A patent/AR105582A1/en unknown
- 2016-08-03 TW TW105124624A patent/TW201718548A/en unknown
-
2018
- 2018-01-30 PH PH12018500239A patent/PH12018500239A1/en unknown
- 2018-01-31 IL IL257264A patent/IL257264A/en unknown
- 2018-03-02 CO CONC2018/0002416A patent/CO2018002416A2/en unknown
- 2018-08-22 HK HK18110806.3A patent/HK1251548A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP6693520B2 (en) | 2020-05-13 |
PT3333165T (en) | 2019-10-29 |
CO2018002416A2 (en) | 2018-06-12 |
IL257264A (en) | 2018-03-29 |
CN107849018A (en) | 2018-03-27 |
RU2018107711A3 (en) | 2019-11-21 |
CA2995188A1 (en) | 2017-02-09 |
RU2731913C2 (en) | 2020-09-09 |
US10301286B2 (en) | 2019-05-28 |
AR105582A1 (en) | 2017-10-18 |
EP3333165A4 (en) | 2019-01-09 |
TW201718548A (en) | 2017-06-01 |
SG11201800882YA (en) | 2018-03-28 |
PL3333165T3 (en) | 2019-12-31 |
CN107849018B (en) | 2021-02-23 |
HK1251548A1 (en) | 2019-02-01 |
US20180230131A1 (en) | 2018-08-16 |
EP3333165A1 (en) | 2018-06-13 |
MX2018001503A (en) | 2018-04-24 |
KR20180032585A (en) | 2018-03-30 |
WO2017022733A1 (en) | 2017-02-09 |
PH12018500239A1 (en) | 2018-08-13 |
EP3333165B1 (en) | 2019-09-18 |
JPWO2017022733A1 (en) | 2018-05-31 |
AU2016302648A1 (en) | 2018-02-22 |
ES2753227T3 (en) | 2020-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201200318A1 (en) | Heterocyclic oximes | |
CA2864222A1 (en) | Cycloalkane derivative | |
EA200901573A1 (en) | Heteroaryl Thiazole Substituents | |
EA201100482A1 (en) | CRYSTAL FORMS OF 2-THIAZOLIL-4-QUINOLINYLOXY DERIVATIVE, ACTIVE HCV INHIBITOR | |
JP2014506907A5 (en) | ||
EA200971026A1 (en) | NEW MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | |
EA201001455A1 (en) | Pyridine and pyrazine as PI3K inhibitors (phosphatidylinositin kinase-3) | |
WO2012018534A3 (en) | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases | |
EA201270546A1 (en) | SUBSTITUTED PIPERIDINES, WHICH INCREASE P53 ACTIVITY AND THEIR APPLICATION | |
JP2015500843A5 (en) | ||
MX358961B (en) | C7-fluoro substituted tetracycline compounds. | |
NZ593848A (en) | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof | |
RU2010144637A (en) | SUBSTITUTED GAMMA-LACTAMS AS THERAPEUTIC AGENTS | |
MY160222A (en) | Polyheterocyclic compounds highly potent as hcv inhibitors | |
NZ607580A (en) | N-heteroaryl compounds | |
IN2014MN02562A (en) | ||
WO2011025982A3 (en) | Tetracycline compounds | |
WO2010129057A3 (en) | Tetracycline compounds | |
RU2017145930A (en) | ROR GAMMA MODULATORS (RORγ) | |
JP2010526819A5 (en) | ||
EA201171339A1 (en) | THE WAY TO REDUCE THE INTRA-GL PRESSURE IN PEOPLE | |
RU2016120763A (en) | RESPIRATORY SYNCITIAL VIRUS INHIBITORS | |
EA201391026A1 (en) | CRYSTALLINE DERIVATIVE OF OXASINE AND ITS APPLICATION AS A BACE INHIBITOR | |
EA201101210A1 (en) | 5- (2 - {[6- (2,2-DIFFOR-2-PHENYLETOXY) HEXIL] AMINO} -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -OH FOR THE TREATMENT OF PULMERARY FUNCTION | |
RU2018107711A (en) | PIPERAZINE DERIVATIVE |